<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97591">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02091557</url>
  </required_header>
  <id_info>
    <org_study_id>CA125_VAS_changes</org_study_id>
    <nct_id>NCT02091557</nct_id>
  </id_info>
  <brief_title>CA 125 and VAS Pain Score Changes to Diagnose Endometriosis</brief_title>
  <official_title>CA 125 and VAS Pain Score Changes Following GnRH-analog Administration as ex Adiuvantibus Criteria to Diagnose Endometriosis as Cause of Chronic Pelvic Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Magna Graecia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Magna Graecia</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the diagnostic accuracy for the noninvasive detection of pelvic endometriosis of
      the combination of two simple parameters: modifications of serum CA 125 and VAS pain score
      following one dose of GnRH-analog (GnRH-a).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Between January 2010 and January 2014, women scheduled for a diagnostic laparoscopy for CPP
      at our Department will be enrolled in the current prospective controlled study. For these
      patients, laparoscopy represents the last diagnostic step after medical history negative for
      gastrointestinal, urological, musculoskeletal and psychoneurological disorders related to
      pelvic pain, physical examination, ultrasonographic assessment and laboratory testing. From
      all patients, at enrollment, blood samples for serum CA125 determination will be taken
      during the early follicular phase (2nd-3rd day of the menstrual cycle) and VAS score for
      menstrual pain will be assessed.  Electrochemiluminescence  immunoassay (Immunoassay Elecsys
      Systems, Roche Diagnostics, Italy) for serum CA125 assay will be used (kit coefficient of
      variation between-run 0.0% and within-run 2.0%).

      During the time passed on surgery waiting list, patients will received leuprolide acetate
      depot (LAD) at a dose of 3.75 mg IM at the 21st day of the menstrual cycle. One month later
      LAD administration, serum CA125 levels and VAS score will be assessed again, and then the
      surgical procedure will be performed in all these patients.

      After laparoscopy and definitive histological examination, the population initially enrolled
      will be sub-grouped according to endometriosis diagnosis in two groups, i.e. group 1
      (subjects with endometriosis) and group 2 (subjects without endometriosis).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Diagnostic accuracy of composite measure (serum CA 125 levels and VAS pain score changes following one dose of GnRH-a)</measure>
    <time_frame>One month after LAD administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Diagnostic accuracy (specificity, sensitivity, AUC and cut off levels) of the modifications of serum CA 125 levels and VAS pain score following one dose of LAD (composite measure)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Pelvic Pain</condition>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>GnRH-analogue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CA125 levels and VAS pain score changes will be assessed after GnRH-a administration in all patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH-analogue</intervention_name>
    <arm_group_label>GnRH-analogue</arm_group_label>
    <other_name>LAD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic pelvic pain

        Exclusion Criteria:

          -  age less than 18 and greater than 38

          -  oligo-amenorrhea

          -  use of hormone medications (including oral contraceptives pill, progestogens, and so
             on)

          -  conditions affecting serum CA125 levels (such as, pregnancy, ovarian endometrioma
             seen at ultrasonography, pelvic inflammatory diseases, neoplasm, tuberculosis,
             hepatitis, peritonitis, recent abdominal surgery and pelvic organic disease)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fulvio Zullo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Magna Graecia University of Catanzaro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chair of Obstetrics and Gynecology - University division - UMG</name>
      <address>
        <city>Catanzaro</city>
        <state>CZ</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 17, 2014</lastchanged_date>
  <firstreceived_date>March 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Magna Graecia</investigator_affiliation>
    <investigator_full_name>Fulvio Zullo</investigator_full_name>
    <investigator_title>Full Professor Obstetric Gynecology</investigator_title>
  </responsible_party>
  <keyword>GnRH-a</keyword>
  <keyword>endometriosis</keyword>
  <keyword>chronic pelvic pain</keyword>
  <keyword>VAS score</keyword>
  <keyword>diagnostic accuracy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Pelvic Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
